Erratum (Retracted article): First-line thalidomide-dexamethasone therapy in preparation for auto-SCT in young patients (<61 years) with symptomatic multiple myeloma (Bone Marrow Transplantation (2005) vol. 36 (193-198) 10.1038/sj.bmt.1705050);First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma (Retraction in: Bone Marrow Transplantation (2009) 43:11 (893))

Bone Marrow Transplantation

Volumn 36, Issue 3, 2005, Pages 193-198

  Abdelkefi, A ^a   Torjman, L ^a   Romdhane, N Ben ^b   Ladeb, S ^a   El Omri, H ^c   Othman, T Ben ^a   Elloumi, M ^d   Bellaj, H ^d   Lakhal, A ^a   Jeddi, R ^e   Aissaoui L ^e   Saad, A ^c   Hsairi M ^f   Boukef, K ^g   Dellagi, K ^h   Abdeladhim, A Ben ^a   Hafsia, A ⁱ   Belhadj, Z ⁱ   Ben Abid, H ⁱ   Ben Lakhal, R ⁱ   Meddeb, B ⁱ   Guermazi, S ⁱ   Mnif, S ⁱ   Amouri, A ⁱ   Louzir, H ⁱ   Maamar, M ⁱ   Slama, H ⁱ   Moojat, N ⁱ   Jenhani, F ⁱ   Ben Hamed, L ⁱ   Turki, I ⁱ   Ben Ayed, F ⁱ   Ben Hadj Yahia, C ⁱ   Zouari, R ⁱ   Belhassine, L ⁱ   Msadek, F ⁱ   Louzir, B ⁱ   Karoui, M ⁱ   Houmane, H ⁱ   Sellami, S ⁱ   El Euch, M ⁱ   Goucha, R ⁱ   Zouaghi, K ⁱ   Souissi, T ⁱ   Hdiji, S ⁱ   Frikha, M ⁱ   Toumi, N ⁱ   Bahloul, Z ⁱ   Hachicha, J ⁱ   Baklouti, S ⁱ   Khlif, A ⁱ   Laatiri, A ⁱ   Zakraoui, L ⁱ   Laatar, M ⁱ   Ksontini, I ⁱ   Bouslama, ⁱ   Ben Dridi, ⁱ   Younes, M ⁱ   Bargaoui, N ⁱ   more..

^a CENTRE NATIONAL DE GREFFE DE MOELLE OSSEUSE   (Tunisia)

^b LA RABTA HOSPITAL   (Tunisia)

^c FARHAT HACHED HOSPITAL   (Tunisia)

^d HEDI CHAKER HOSPITAL   (Tunisia)

^e Hopital Aziza Othmana   (Tunisia)

^f Inst National de la Sante Publique   (Tunisia)

^g Centre National de Transfusion Sanguine Tunis   (Tunisia)

^h PASTEUR INSTITUTE OF TUNIS   (Tunisia)

ⁱ Institut Pasteur de Tunis ^*

Author keywords

Dexamethasone; Engraftment; Multiple myeloma; Stem cell transplantation; Thalidomide

Indexed keywords

ACENOCOUMAROL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; THALIDOMIDE;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER STAGING; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; INFECTION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUROPATHY; PRIMARY HEALTH CARE; PRIORITY JOURNAL; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

EID: 23744432513     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.113     Document Type: Erratum

References (31)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
2. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myelome. N Engl J Med 1996; 335: 91-97.
3. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
4. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
5. Rajkumar SV, Kyle RA. Angiogenesis in multiple myeloma. Semin Oncol 2001; 28: 560-564.
6. Stirling D. Thalidomide: a novel template for anticancer drugs. Semin Oncol 2001; 28: 602-606.
7. Kumar S, Witzig TE, Dispenzieri A et al. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 2004; 18: 624-627.
8. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
9. Tosi P, Zamagni E, Cellini C et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002; 87: 934-942.
10. Dimopoulos MA, Zervas K, Kouvatseas G et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991-995.
11. Anagnostopoulos A, Weber D, Rankin K et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121: 768-771.
12. Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-4323.
13. Weber D, Rankin K, Gavino M et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
14. Cavo M, Zamagni E, Tosi P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89: 826-831.
15. Abdelkefi A, Ben Romdhane N, Younes M et al. Activated protein C resistance in the absence of factor V Leiden mutation is associated with an increased risk of thrombotic complications in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Haema 2005; 8: 118-120.
16. Bladè J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated with high-dose therapy and hematopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
17. Vacca A, Ribatti D, Roncali L et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503-508.
18. Rajkumar SV, Fonseca R, Witzig TE et al. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 1999; 13: 469-472.
19. D'Amato RJ, Loughnan MS, Flynn E et al. Thalidomide is an inhibitor of angiogenesis. Proc Natn Acad Sci USA 1994; 91: 4082-4085.
20. Juliusson G, Celsing F, Turesson I et al. Frequent good partial remissions from thalidomide including best response even in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000; 109: 89-96.
21. Barlogie B, Desikan R, Eddlemon P et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
22. Yacoub-Agha I, Attal M, Dumontet C et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients-report of the intergroupe francophone du myélome. Hematol J 2002; 3: 185-192.
23. Mileshkin L, Biagi JJ, Mitchell P et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102: 69-77.
24. The UK Myeloma Forum Guidelines Working Group. Diagnosis and management of multiple myeloma. Br J Haematol 2001; 115: 522-540.
25. Cavo M, Benni M, Ronconi S et al. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Haematologica 2002; 87: 934-942.
26. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary therapy for multiple myeloma. Am J Hematol 1990; 33: 86-89.
27. Zangari M, Saghafifar F, Anaissie F et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002; 13: 187-192.
28. Goldschmidt H, Hegenbart U, Wallmeier M et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736-744.
29. Prince HM, Imrie K, Sutherland DR et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. Br J Haematol 1996; 93: 142-145.
30. Gertz MA, Lacy MQ, Inwards DJ et al. Factors influencing platelet recovery after blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant 1997; 20: 375-380.
31. Ghobrial IM, Dispenzieri A, Bundy KL et al. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant 2003; 32: 587-592.